Floatz logo

Zilovertamab

Marginal Zone Lymphoma

Oncternal Therapeutics, Incmonoclonal_antibodyPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

106 Active assets in the Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Zilovertamab is also rated in:

mantle cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
lymphoproliferative syndromeDormant
B
Indicative ·
60 / 100
View asset →
lymphatic system disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →